SG11201803493UA - Genetically modified cells and uses thereof - Google Patents
Genetically modified cells and uses thereofInfo
- Publication number
- SG11201803493UA SG11201803493UA SG11201803493UA SG11201803493UA SG11201803493UA SG 11201803493U A SG11201803493U A SG 11201803493UA SG 11201803493U A SG11201803493U A SG 11201803493UA SG 11201803493U A SG11201803493U A SG 11201803493UA SG 11201803493U A SG11201803493U A SG 11201803493UA
- Authority
- SG
- Singapore
- Prior art keywords
- genetically modified
- modified cells
- cells
- genetically
- modified
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001152—Transcription factors, e.g. SOX or c-MYC
- A61K39/001153—Wilms tumor 1 [WT1]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
- A61K39/001111—Immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/48—Reproductive organs
- A61K35/54—Ovaries; Ova; Ovules; Embryos; Foetal cells; Germ cells
- A61K35/545—Embryonic stem cells; Pluripotent stem cells; Induced pluripotent stem cells; Uncharacterised stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001169—Tumor associated carbohydrates
- A61K39/00117—Mucins, e.g. MUC-1
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/463—Cellular immunotherapy characterised by recombinant expression
- A61K39/4631—Chimeric Antigen Receptors [CAR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/463—Cellular immunotherapy characterised by recombinant expression
- A61K39/4632—T-cell receptors [TCR]; antibody T-cell receptor constructs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464402—Receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464402—Receptors, cell surface antigens or cell surface determinants
- A61K39/464416—Receptors for cytokines
- A61K39/464417—Receptors for tumor necrosis factors [TNF], e.g. lymphotoxin receptor [LTR], CD30
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464402—Receptors, cell surface antigens or cell surface determinants
- A61K39/464429—Molecules with a "CD" designation not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464452—Transcription factors, e.g. SOX or c-MYC
- A61K39/464453—Wilms tumor 1 [WT1]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70517—CD8
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3076—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
- C07K16/3092—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties against tumour-associated mucins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
- C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/27—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by targeting or presenting multiple antigens
- A61K2239/29—Multispecific CARs
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
- C12N2506/45—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from artificially induced pluripotent stem cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2015904933A AU2015904933A0 (en) | 2015-11-27 | Genetically modified cells and uses thereof | |
AU2016901328A AU2016901328A0 (en) | 2016-04-11 | Genetically modified cells and uses thereof - III | |
PCT/AU2016/051141 WO2017088012A1 (en) | 2015-11-27 | 2016-11-23 | Genetically modified cells and uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201803493UA true SG11201803493UA (en) | 2018-05-30 |
Family
ID=58762790
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201803493UA SG11201803493UA (en) | 2015-11-27 | 2016-11-23 | Genetically modified cells and uses thereof |
SG10201912825XA SG10201912825XA (en) | 2015-11-27 | 2016-11-23 | Genetically modified cells and uses thereof |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG10201912825XA SG10201912825XA (en) | 2015-11-27 | 2016-11-23 | Genetically modified cells and uses thereof |
Country Status (11)
Country | Link |
---|---|
US (2) | US11400145B2 (en) |
EP (3) | EP3708587A1 (en) |
JP (3) | JP6976960B2 (en) |
CN (2) | CN109152824B (en) |
AU (2) | AU2016361451B2 (en) |
CA (1) | CA3004120A1 (en) |
ES (1) | ES2862907T3 (en) |
IL (2) | IL296410A (en) |
MY (1) | MY189819A (en) |
SG (2) | SG11201803493UA (en) |
WO (1) | WO2017088012A1 (en) |
Families Citing this family (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11525119B2 (en) | 2016-09-06 | 2022-12-13 | The Children's Medical Center Corporation | Immune cells derived from induced pluripotent stem cell |
CN110621335A (en) | 2017-03-17 | 2019-12-27 | 弗雷德哈钦森癌症研究中心 | Immunomodulatory fusion proteins and uses thereof |
MX2019011897A (en) * | 2017-04-18 | 2019-11-28 | Fujifilm Cellular Dynamics Inc | Antigen-specific immune effector cells. |
AU2018352984B2 (en) * | 2017-10-18 | 2024-02-01 | Precigen, Inc. | Polypeptide compositions comprising spacers |
TW201930340A (en) | 2017-12-18 | 2019-08-01 | 美商尼恩醫療公司 | Neoantigens and uses thereof |
CN109971716B (en) * | 2017-12-28 | 2023-08-01 | 上海细胞治疗研究院 | EGFR-specific CAR-T cells from autocrine CD47 antibodies and uses thereof |
CN109971721B (en) * | 2017-12-28 | 2023-10-31 | 上海细胞治疗研究院 | Interval Pi Sute-specific CAR-T cells from CD 47-expressing antibodies and uses thereof |
KR20200120673A (en) * | 2018-02-11 | 2020-10-21 | 메모리얼 슬로안 케터링 캔서 센터 | Non-HLA restricted T cell receptor and uses thereof |
US20210085715A1 (en) * | 2018-02-23 | 2021-03-25 | Cartherics Pty. Ltd. | T cell disease treatment targeting tag-72 |
GB201804701D0 (en) * | 2018-03-23 | 2018-05-09 | Gammadelta Therapeutics Ltd | Lymphocytes expressing heterologous targeting constructs |
GB201807945D0 (en) * | 2018-05-16 | 2018-06-27 | Ospedale San Raffaele Srl | Vector production |
EP3801568A4 (en) * | 2018-05-31 | 2022-03-16 | Washington University | Genome-edited invariant natural killer t (inkt) cells for the treatment of hematologic malignancies |
CA3108381A1 (en) * | 2018-08-01 | 2020-02-06 | City Of Hope | Tag72 targeted chimeric antigen receptor modified t cells for treatment of tag72-positive tumors |
AU2020291457A1 (en) * | 2019-06-12 | 2022-02-10 | The Regents Of The University Of California | Engineered off-the-shelf immune cells and methods of use thereof |
US20230000915A1 (en) * | 2019-11-25 | 2023-01-05 | Kyoto University | T-cell master cell bank |
KR20230013257A (en) * | 2020-05-22 | 2023-01-26 | 충칭 프리시젼 바이오테크 컴퍼니 리미티드 | Fusion proteins and their applications for reversal of the tumor microenvironment |
KR20230042691A (en) | 2020-06-04 | 2023-03-29 | 카리스마 테라퓨틱스 인코포레이티드 | Novel constructs for chimeric antigen receptors |
WO2022061837A1 (en) * | 2020-09-27 | 2022-03-31 | Jiangsu Cell Tech Medical Research Institute Co., Ltd. | Fibronectin extra domain b (edb) -specific car-t for cancer |
US11591381B2 (en) | 2020-11-30 | 2023-02-28 | Crispr Therapeutics Ag | Gene-edited natural killer cells |
CN117441010A (en) * | 2021-04-07 | 2024-01-23 | 世纪治疗股份有限公司 | Compositions and methods for producing alpha-beta T cells from induced pluripotent stem cells |
WO2023110824A1 (en) * | 2021-12-15 | 2023-06-22 | Novo Nordisk A/S | Novel integrin associated protein (iap) |
CN114573710A (en) * | 2022-02-16 | 2022-06-03 | 南方医科大学珠江医院 | Immune cell for simultaneously secreting CD47 antibody through target antigen and application thereof |
Family Cites Families (54)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5585362A (en) | 1989-08-22 | 1996-12-17 | The Regents Of The University Of Michigan | Adenovirus vectors for gene therapy |
US5350674A (en) | 1992-09-04 | 1994-09-27 | Becton, Dickinson And Company | Intrinsic factor - horse peroxidase conjugates and a method for increasing the stability thereof |
US5786146A (en) | 1996-06-03 | 1998-07-28 | The Johns Hopkins University School Of Medicine | Method of detection of methylated nucleic acid using agents which modify unmethylated cytosine and distinguishing modified methylated and non-methylated nucleic acids |
WO1998018809A1 (en) | 1996-10-25 | 1998-05-07 | Cell Genesys, Inc. | Targeted cytolysis of cancer cells |
US6908763B1 (en) | 1997-08-22 | 2005-06-21 | The Board Of Trustees Of The Leland Stanford Junior University | Mammalian common lymphoid progenitor cell |
US6331393B1 (en) | 1999-05-14 | 2001-12-18 | University Of Southern California | Process for high-throughput DNA methylation analysis |
US6761883B2 (en) | 1999-06-29 | 2004-07-13 | The Board Of Trustees Of The Leland Stanford Junior University | Mammalian myeloid progenitor cell subsets |
ES2293912T3 (en) | 1999-06-29 | 2008-04-01 | The Board Of Trustees Of The Leland Stanford Junior University | SUBGROUPS OF MELIFEROUS MYELOID PROGENITOR CELLS. |
AU1086501A (en) | 1999-10-15 | 2001-04-30 | Carnegie Institution Of Washington | Rna interference pathway genes as tools for targeted genetic interference |
US6326193B1 (en) | 1999-11-05 | 2001-12-04 | Cambria Biosciences, Llc | Insect control agent |
AU2001275474A1 (en) | 2000-06-12 | 2001-12-24 | Akkadix Corporation | Materials and methods for the control of nematodes |
DE10130800B4 (en) | 2001-06-22 | 2005-06-23 | Epigenomics Ag | Method for the detection of cytosine methylation with high sensitivity |
US7446190B2 (en) * | 2002-05-28 | 2008-11-04 | Sloan-Kettering Institute For Cancer Research | Nucleic acids encoding chimeric T cell receptors |
EP1530418A4 (en) | 2002-05-31 | 2005-10-12 | Univ Leland Stanford Junior | Methods of identifying and isolating stem cells and cancer stem cells |
US7592174B2 (en) | 2002-05-31 | 2009-09-22 | The Board Of Trustees Of The Leland Stanford Junior University | Isolation of mesenchymal stem cells |
AU2003272369A1 (en) | 2002-09-13 | 2004-04-30 | The Board Of Trustees Of The Leland Stanford Junior University | Mammalian megakaryocyte progenitor cell |
US20050129671A1 (en) | 2003-03-11 | 2005-06-16 | City Of Hope | Mammalian antigen-presenting T cells and bi-specific T cells |
WO2005021594A2 (en) | 2003-08-29 | 2005-03-10 | The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services | Minimally immunogenic variants of sdr-grafted humanized antibody cc49 and their use |
AU2004279742A1 (en) * | 2003-10-08 | 2005-04-21 | Kyowa Hakko Kirin Co., Ltd. | Fused protein composition |
WO2005057172A2 (en) | 2003-12-05 | 2005-06-23 | The Board Of Trustees Of The Leland Stanford Junior University | Identification, isolation and elimination of cancer stem cells |
WO2005123909A2 (en) | 2004-06-09 | 2005-12-29 | The Board Of Trustees Of The Leland Stanford Junior University | Isolation and characterization of muscle regenerating cells |
US7641897B2 (en) | 2004-11-23 | 2010-01-05 | The Board Of Trustees Of The Leland Stanford Junior University | Feeder layer and serum independent embryonic stem cells |
WO2006089218A2 (en) | 2005-02-17 | 2006-08-24 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and compositions for modulating angiogenesis |
WO2006116076A2 (en) * | 2005-04-28 | 2006-11-02 | Genencor International, Inc. | Tab molecules |
US7514229B2 (en) | 2005-09-29 | 2009-04-07 | The Board Of Trustees Of The Leland Stanford Junior University | Methods for diagnosing and evaluating treatment of blood disorders |
US8377448B2 (en) | 2006-05-15 | 2013-02-19 | The Board Of Trustees Of The Leland Standford Junior University | CD47 related compositions and methods for treating immunological diseases and disorders |
US8236313B2 (en) | 2006-10-06 | 2012-08-07 | The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services | Prevention of tissue ischemia, related methods and compositions |
EP2097535B1 (en) | 2006-12-07 | 2016-09-21 | The Board of Trustees of the Leland Stanford Junior University | Identification and isolation of acute myeloid leukemia stem cells |
US7781179B2 (en) | 2006-12-07 | 2010-08-24 | The Board Of Trustees Of The Leland Stanford Junior University | Identification and isolation of transitional cell carcinoma stem cells |
US8765390B2 (en) | 2006-12-08 | 2014-07-01 | The Board Of Trustees Of The Leland Stanford Junior University | Identification and isolation of squamous carcinoma stem cells |
ES2582340T3 (en) | 2008-01-15 | 2016-09-12 | The Board Of Trustees Of The Leland Stanford Junior University | Methods for manipulating phagocytosis mediated by CD47 |
AU2009205706B2 (en) | 2008-01-15 | 2015-03-19 | The Board Of Trustees Of The Leland Stanford Junior University | Markers of acute myeloid leukemia stem cells |
EP2279253B1 (en) | 2008-04-09 | 2016-11-16 | Maxcyte, Inc. | Engineering and delivery of therapeutic compositions of freshly isolated cells |
US8320687B2 (en) | 2009-02-05 | 2012-11-27 | The Board Of Trustees Of The Leland Stanford Junior University | Universal lossy compression methods |
CA2766409C (en) | 2009-07-03 | 2023-04-25 | Avipep Pty Ltd | Immuno-conjugates and methods for producing them |
SI2477648T1 (en) | 2009-09-15 | 2022-09-30 | The Board Of Trustees Of The Leland Stanford Junior University | Synergistic anti-cd47 therapy for hematologic cancers |
US9151760B2 (en) | 2009-09-29 | 2015-10-06 | The Board Of Trustees Of The Leland Stanford Junior University | Isolation and use of melanoma cancer stem cells |
US9175079B2 (en) | 2010-01-29 | 2015-11-03 | The Board Of Trustees Of The Leland Stanford Junior University | Depletion of teratoma-forming pluripotent stem cells |
PT2569013T (en) | 2010-05-14 | 2017-02-08 | Univ Leland Stanford Junior | Humanized and chimeric monoclonal antibodies to cd47 |
ES2754394T3 (en) | 2010-09-08 | 2020-04-17 | Chemotherapeutisches Forschungsinstitut Georg Speyer Haus | Chimeric antigen receptors with an optimized hinge region |
CN108103085A (en) | 2010-12-09 | 2018-06-01 | 宾夕法尼亚大学董事会 | The purposes of the T cell treating cancer of Chimeric antigen receptor-modification |
CN103442768A (en) | 2011-01-18 | 2013-12-11 | 宾夕法尼亚大学董事会 | Compositions and methods for treating cancer |
WO2013063419A2 (en) | 2011-10-28 | 2013-05-02 | The Trustees Of The University Of Pennsylvania | A fully human, anti-mesothelin specific chimeric immune receptor for redirected mesothelin-expressing cell targeting |
JP2015513399A (en) * | 2012-02-22 | 2015-05-14 | ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア | Compositions and methods for generating surviving populations of T cells useful for the treatment of cancer |
EP2836239A1 (en) | 2012-04-11 | 2015-02-18 | The United States of America, as Represented By the Secretary, Department of Health and Human Services | Chimeric antigen receptors targeting b-cell maturation antigen |
EP2872526B1 (en) * | 2012-07-13 | 2020-04-01 | The Trustees of the University of Pennsylvania | Enhancing activity of car t cells by co-introducing a bispecific antibody |
LT2872171T (en) | 2012-07-13 | 2021-04-26 | The Trustees Of The University Of Pennsylvania | Toxicity management for anti-tumor activity of cars |
US9045734B2 (en) | 2012-07-31 | 2015-06-02 | The Board Of Trustees Of The Leland Stanford Junior University | Isolation and characterization of progenitor cells from mesothelium |
WO2014075788A1 (en) | 2012-11-13 | 2014-05-22 | Biontech Ag | Agents for treatment of claudin expressing cancer diseases |
EP2931751B1 (en) | 2012-12-12 | 2020-02-05 | Arch Oncology, Inc. | Therapeutic cd47 antibodies |
US9221908B2 (en) | 2012-12-12 | 2015-12-29 | Vasculox, Inc. | Therapeutic CD47 antibodies |
DK2981607T3 (en) * | 2013-04-03 | 2020-11-16 | Memorial Sloan Kettering Cancer Center | EFFICIENT GENERATION OF TUMOR-TARGETED T-CELLS DERIVED FROM PLURIPOTENT STEM CELLS |
US20180214527A1 (en) * | 2015-03-26 | 2018-08-02 | City Of Hope | Bi-specific targeted chimeric antigen receptor t cells |
CN105331586B (en) * | 2015-11-20 | 2020-09-15 | 上海细胞治疗研究院 | Tumor precision T cell containing efficient killing and initiating mechanism and application thereof |
-
2016
- 2016-11-23 US US15/778,836 patent/US11400145B2/en active Active
- 2016-11-23 EP EP20169645.7A patent/EP3708587A1/en active Pending
- 2016-11-23 EP EP16867445.5A patent/EP3380117B1/en active Active
- 2016-11-23 WO PCT/AU2016/051141 patent/WO2017088012A1/en active Application Filing
- 2016-11-23 SG SG11201803493UA patent/SG11201803493UA/en unknown
- 2016-11-23 SG SG10201912825XA patent/SG10201912825XA/en unknown
- 2016-11-23 IL IL296410A patent/IL296410A/en unknown
- 2016-11-23 AU AU2016361451A patent/AU2016361451B2/en active Active
- 2016-11-23 CN CN201680069543.6A patent/CN109152824B/en active Active
- 2016-11-23 CA CA3004120A patent/CA3004120A1/en active Pending
- 2016-11-23 CN CN202211541314.3A patent/CN116121281A/en active Pending
- 2016-11-23 JP JP2018546725A patent/JP6976960B2/en active Active
- 2016-11-23 EP EP20169648.1A patent/EP3708588A1/en active Pending
- 2016-11-23 ES ES16867445T patent/ES2862907T3/en active Active
- 2016-11-23 MY MYPI2018701648A patent/MY189819A/en unknown
-
2018
- 2018-05-24 IL IL259586A patent/IL259586B2/en unknown
-
2021
- 2021-11-10 JP JP2021183110A patent/JP2022027762A/en active Pending
-
2022
- 2022-06-09 US US17/836,052 patent/US20220305106A1/en active Pending
-
2024
- 2024-01-08 AU AU2024200108A patent/AU2024200108A1/en active Pending
- 2024-01-26 JP JP2024010098A patent/JP2024028648A/en active Pending
Also Published As
Publication number | Publication date |
---|---|
AU2016361451A9 (en) | 2019-01-03 |
AU2016361451A1 (en) | 2018-06-07 |
AU2024200108A1 (en) | 2024-01-25 |
US20220305106A1 (en) | 2022-09-29 |
JP2022027762A (en) | 2022-02-14 |
IL296410A (en) | 2022-11-01 |
MY189819A (en) | 2022-03-10 |
EP3380117B1 (en) | 2021-01-06 |
CN109152824A (en) | 2019-01-04 |
EP3380117A1 (en) | 2018-10-03 |
JP2024028648A (en) | 2024-03-04 |
CN109152824B (en) | 2022-12-06 |
WO2017088012A1 (en) | 2017-06-01 |
CN116121281A (en) | 2023-05-16 |
EP3380117A4 (en) | 2019-04-03 |
SG10201912825XA (en) | 2020-02-27 |
CA3004120A1 (en) | 2017-06-01 |
JP2018535701A (en) | 2018-12-06 |
US11400145B2 (en) | 2022-08-02 |
WO2017088012A9 (en) | 2018-06-07 |
AU2016361451B2 (en) | 2024-01-25 |
US20180353588A1 (en) | 2018-12-13 |
JP6976960B2 (en) | 2021-12-08 |
EP3708587A1 (en) | 2020-09-16 |
IL259586B2 (en) | 2023-02-01 |
ES2862907T3 (en) | 2021-10-08 |
IL259586A (en) | 2018-07-31 |
IL259586B (en) | 2022-10-01 |
EP3708588A1 (en) | 2020-09-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG10201912825XA (en) | Genetically modified cells and uses thereof | |
HK1250741A1 (en) | Modified gamma delta cells and uses thereof | |
HK1250481A1 (en) | Modified t cells and methods of making and using the same | |
IL258666A (en) | Natural killer cells and ilc3 cells and uses thereof | |
IL253248A0 (en) | Natural killer cells and uses thereof | |
SG11201609118RA (en) | Modified natural killer cells and uses thereof | |
IL249970A0 (en) | Gamma delta t cells and uses thereof | |
GB201522097D0 (en) | Cells | |
IL259202A (en) | Modified immune cells and uses thereof | |
GB201616238D0 (en) | Modified T cells | |
SI3131577T1 (en) | Modified host cells and uses thereof | |
ZA201900891B (en) | B-cell-mimetic cells | |
IL273247A (en) | Novel cell line and uses thereof | |
GB201519554D0 (en) | Genetically modified microorganisms | |
GB201604427D0 (en) | Modified cell | |
AU2015904933A0 (en) | Genetically modified cells and uses thereof | |
AU2015904935A0 (en) | Genetically modified cells and uses thereof - II | |
GB201616232D0 (en) | Novel cell line and uses thereof | |
AU2016901328A0 (en) | Genetically modified cells and uses thereof - III | |
GB201622225D0 (en) | Modified host cells and uses thereof | |
GB201415379D0 (en) | Gamma T cells and uses thereof | |
GB201412175D0 (en) | Gamma T cells and uses thereof | |
GB201506317D0 (en) | Hepatocyte-like cells and related cell lines | |
GB201420709D0 (en) | Electrochemical cells and components thereof | |
IL236273A0 (en) | Battery cells and arrangements |